NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Reducing inflammation helps create a regenerative environment in the Central Nervous SystemTORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome product. “Inflammation and regeneration are conflicting bi ...